|
13 Dec 2019 |
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
|
|
13 Dec 2019 |
Silverback Therapeutics Announces Preclinical Data at 2019 San Antonio Breast Cancer Symposium (SABCS) Supporting Development of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies
|
|
13 Dec 2019 |
Innate Pharma provides update on lacutamab TELLOMAK trial
|
|
13 Dec 2019 |
Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
|
|
13 Dec 2019 |
Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
|
|
12 Dec 2019 |
Genentech’s Fixed-dose Subcutaneous Combination of Perjeta and Herceptin Comparable to Intravenous Formulations in People With HER2-positive Breast Cancer
|
|
12 Dec 2019 |
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
|
|
11 Dec 2019 |
Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
|
|
11 Dec 2019 |
NeoImmuneTech Announces Clinical Collaboration to Evaluate Hyleukin-7™ (NT-I7) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
|
|
11 Dec 2019 |
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
|
|
11 Dec 2019 |
The Next Wave of Biosimilar Antibodies: new report analyzes competition in development of biosimilar antibodies for Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More
|
|
11 Dec 2019 |
AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901
|
|
11 Dec 2019 |
Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
|
|
11 Dec 2019 |
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
|
|
11 Dec 2019 |
Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
|
|
11 Dec 2019 |
Darzalex (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
|
|
11 Dec 2019 |
LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD
|
|
11 Dec 2019 |
BioInvent and Transgene announce compelling preclinical data for BT-001 in solid tumors
|
|
11 Dec 2019 |
FDA Accepts Supplemental Biologics License Application for Xolair (Omalizumab) for the Treatment of Nasal Polyps
|
|
11 Dec 2019 |
First patient dosed in BIVV001 phase 3 XTEND-1 study in people with severe haemophilia A
|
|
10 Dec 2019 |
ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
|
|
10 Dec 2019 |
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
|
|
10 Dec 2019 |
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
|
|
10 Dec 2019 |
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody
|
|
10 Dec 2019 |
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma
|
